MedTrace Logo

A Single-dose Study to Investigate the Effects of 4 Different Doses of Inhaled AZD8683 in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT01708057 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2014-01-15

Study results available
· View outcomes & findings →

Summary

This study in Chronic Obstructive Pulmonary Disease (COPD) patients will investigate the bronchodilatory effect of AZD8683. AZD8683 will be tested versus placebo and an active comparator.

Conditions

Interventions

DRUG

AZD8683

AZD8683 administered via inhalation

DRUG

Placebo

Placebo administered via inhalation

DRUG

Tiotropium

Tiotropium administered via inhalation

Sponsors & Collaborators

Principal Investigators

  • Carin Jorup, MD · AstraZeneca R&DMolndal, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • Poland
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01708057 on ClinicalTrials.gov